Goldenrod

Metadata

Note: European goldenrod (S. virgaurea) should be distinguished from Giant goldenrod (S. gigantea) and Canadian goldenrod (S. canadensis), which are also used medicinally but have somewhat different compositions. Commission E monographs cover all three species, but S. virgaurea is the primary European species.

Approved Indications

Commission E (Germany)

• Approved: Irrigation therapy for:
  • Inflammatory diseases of the lower urinary tract
  • Urinary calculi (stones)
  • Renal gravel (Nierengruess)
  • Prevention of urinary stones and renal gravel

ESCOP

• Approved: Irrigation of the urinary tract, especially in cases of:
  • Inflammation
  • Renal gravel
  • As adjunctive therapy in treatment of bacterial urinary tract infections

EMA/HMPC

• Traditional Use: Herbal medicinal product to increase urine volume and thus as an adjuvant in treatment of minor urinary complaints
• Based on long-standing use (at least 30 years, including 15 years within EU)

Agreement/Disagreement

• Excellent agreement across all three European bodies on the core indication (irrigation therapy for urinary tract inflammation)
• Commission E and ESCOP are slightly more expansive (including renal gravel and stone prevention)
• EMA/HMPC is more conservative in its wording (“minor urinary complaints”)
• US/Anglophone: Essentially unknown in mainstream medicine; not recognized by FDA or major US guidelines
• The concept of “irrigation therapy” itself is largely absent from US medical practice

Conditions Treated

• Urinary tract inflammation (lower urinary tract)
• Renal gravel and urinary calculi prevention
• Adjunctive treatment of bacterial UTIs (supportive, not primary antimicrobial)
• General irritation of the urinary tract
• Minor urinary complaints (dysuria, frequency)

The Concept of Irrigation Therapy (Durchspuelungstherapie)

A distinctly German/European therapeutic approach in which:

1. A diuretic herb is administered to increase urine volume
2. The patient must drink copious fluids (minimum 2 liters/day)
3. The increased urine flow mechanically flushes bacteria, inflammatory mediators, and small calculi from the urinary tract
4. The herb’s anti-inflammatory and spasmolytic properties provide additional symptomatic relief
5. This is always an adjunctive therapy — not a replacement for antibiotics in confirmed infection

Mechanism of Action

Primary Mechanisms

1. Diuretic Effect (Aquaretic)

   • Increases urine volume without significant electrolyte loss (aquaretic rather than true diuretic)
   • Mechanism likely involves flavonoid-mediated effects on renal blood flow and glomerular filtration
   • In vivo animal studies confirm dose-dependent diuretic activity

2. Anti-inflammatory Activity

   • Saponins and leiocarposide stimulate ACTH release from pituitary cells, leading to endogenous glucocorticoid production with anti-inflammatory effects
   • Inhibition of inflammatory mediators in urinary tract tissue
   • In vitro and in vivo confirmation

3. Spasmolytic Effect

   • Modest relaxation of smooth muscle (ex vivo guinea pig gut data shows <15% of papaverine effect)
   • May relieve spasm in urinary tract smooth muscle
   • Contributes to relief of dysuria and colicky pain from renal gravel

4. Analgesic Activity

   • Leiocarposide demonstrated analgesic effects comparable to aminophenazone (for first hour) in mouse hot-plate test
   • Short-duration analgesic effect

5. Antimicrobial Activity [UNCERTAIN]

   • Some in vitro antibacterial activity demonstrated
   • In vitro studies suggest potential synergy with antibiotics against uropathogenic E. coli
   • Clinical significance of antimicrobial effect is unclear; goldenrod is not used as a primary antimicrobial

Key Bioactive Compounds

• Flavonoids: Quercetin, kaempferol, and their glycosides (rutin, quercitrin, astragalin, nicotiflorin) — diuretic and anti-inflammatory
• Saponins: Virgaureasaponins and solidagosaponins — anti-inflammatory via ACTH stimulation
• Leiocarposide: Phenol glycoside — analgesic and anti-inflammatory
• Phenolic acids: Caffeic acid, chlorogenic acid
• Essential oil: Minor component with antimicrobial properties
• Diterpenes and triterpene saponins

Clinical Evidence Summary

Pharmacological Studies

• In vitro: Demonstrated spasmolytic, anti-inflammatory, and antimicrobial effects
• In vivo (animal): Confirmed diuretic, anti-inflammatory, and analgesic properties
• The pharmacological profile is well-characterized and provides a plausible rationale for clinical use

Clinical Studies

• Limited number of controlled clinical trials
• Larger observational/open studies show:
  • Therapeutic effect manifest within 2-4 weeks
  • Side effects rare (frequency <0.3% in larger studies)
  • Effects limited to mild GI disorders and allergic reactions
• [Source: Kidneys Journal review]

Combination Studies

• Often studied as part of multi-herb irrigation therapy formulations
• Difficult to isolate goldenrod’s specific contribution in combination products

Evidence Limitations

• No large, rigorous RCTs specific to S. virgaurea as monotherapy
• The irrigation therapy concept makes placebo-controlled trials difficult (patients know if they are drinking extra fluids)
• Most evidence is pharmacological rather than clinical
• The traditional use basis is strong but the clinical trial basis is weak by modern EBM standards

European vs US/Anglophone Consensus

Safety Profile

Contraindications

• Known hypersensitivity to Asteraceae/Compositae family (cross-reactivity with ragweed, daisies, chrysanthemums)
• Conditions requiring reduced fluid intake (severe cardiac insufficiency, severe renal failure) — because irrigation therapy mandates high fluid intake
• Not to be used in cases of edema due to cardiac or renal failure

Drug Interactions

• Diuretics: Potential additive diuretic effect
• Lithium: Diuretic effect may alter lithium levels
• Antihypertensives: Possible additive hypotensive effect
• No significant drug interactions have been formally documented

Side Effects

• Rare (<0.3% in larger studies): Mild GI disturbances, allergic reactions
• Very rare: Contact dermatitis in sensitized individuals (Asteraceae allergy)
• Overall: Excellent safety profile

Pregnancy/Lactation

• Insufficient safety data; not recommended during pregnancy or lactation as a precaution
• No evidence of teratogenicity, but traditional precautionary avoidance

Clinical Dosage

Standardized Dosage Forms

Key Standardized Products

• Solidago Steiner (Germany): Goldenrod herb extract
• Cystinol (Germany): Combination product containing goldenrod
• Phytodolor (Germany): Multi-herb product including goldenrod (for rheumatic complaints, different indication)
• Solidagoren (Germany): Liquid goldenrod extract

Critical: Fluid Intake Requirement

• During irrigation therapy, patients MUST maintain fluid intake of at least 2 liters per day
• This is not optional — the therapeutic effect depends on the combination of herb + high fluid volume
• Failure to maintain adequate hydration negates the therapeutic approach

Duration of Treatment

• 2-4 weeks for initial therapeutic effect
• Can be used long-term for prevention of urinary stones/gravel
• Consult physician if symptoms persist beyond 2 weeks or worsen

Sources

• EMA Assessment Report on Solidago virgaurea herba
• EMA Community Herbal Monograph
• ESCOP Monograph — Solidaginis virgaureae herba
• Solidago virgaurea Review (PMC)
• Altmeyers Encyclopedia — Solidaginis virgaureae herba
• Arzneipflanzenlexikon — Goldenrod
• Goldenrod + Antibiotics in vitro (PMC)
• Kidneys Journal — Goldenrod for Urinary Tract

Connections

• See Horsetail and Birch Leaf for other irrigation therapy herbs
• See Bearberry Uva Ursi for a UTI treatment herb (different approach: antiseptic vs. irrigation)